Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.Licence and Co-Development Agreement • August 14th, 2006 • Emergent BioSolutions Inc. • Delaware
EMERGENT EUROPE LIMITED, a company organised and existing under the laws of England (Company number 03270465) and having its registered office at 545 Eskdale Road, Winnersh Triangle, Wokingham, Berkshire, RG41 5TU (“Emergent”);
AMENDED & RESTATED LICENCE AND CO-DEVELOPMENT AGREEMENTLicence and Co-Development Agreement • November 22nd, 2022 • Apollomics Inc. • Pharmaceutical preparations • England
This Amended and Restated Licence and Co-Development Agreement (the “Agreement”) is entered into by and between TYG oncology Ltd., a UK Limited Company (“TYG” or “Licensor”), with its address at Synergy House 7 Acorn Business Park Commercial Gate Mansfield, Nottinghamshire NG 18 1EX UK; and Apollomics (Hong Kong) Limited, a Hong Kong entity (with company number 2844212) having one of its places of business at 989 E Hillsdale Blvd, Ste 220, Foster City, CA 94404, USA (“Apollomics”), as of the date last signed by the parties hereto (the “Amendment Date”) and amends and restates the Original Agreement (as defined below).
